Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jette Junge

Showing results (11-20 of 32) with videos related to

Pageof 4
Sort By:
International Journal of Cancer|December 5, 2014
Long-term risk of cervical intraepithelial neoplasia grade 3 or worse according to high-risk human papillomavirus genotype and semi-quantitative viral load among 33,288 women with normal cervical cytologyLouise T Thomsen, Kirsten Frederiksen, Christian Munk, et al.
Gynecologic Oncology|November 13, 2016
A nationwide study of ovarian serous borderline tumors in Denmark 1978-2002. Risk of recurrence, and development of ovarian serous carcinomaCharlotte Gerd Hannibal, Russell Vang, Jette Junge, et al.
The American Journal of Surgical Pathology|March 2, 2017
Long-term Behavior of Serous Borderline Tumors Subdivided Into Atypical Proliferative Tumors and Noninvasive Low-grade Carcinomas: A Population-based Clinicopathologic Study of 942 CasesRussell Vang, Charlotte G Hannibal, Jette Junge, et al.
International Journal of Cancer|March 24, 2016
Human papillomavirus mRNA and DNA testing in women with atypical squamous cells of undetermined significance: A prospective cohort studyLouise T Thomsen, Christian Dehlendorff, Jette Junge, et al.
The American Journal of Surgical Pathology|October 15, 2011
Papillary tubal hyperplasia: the putative precursor of ovarian atypical proliferative (borderline) serous tumors, noninvasive implants, and endosalpingiosisRobert J Kurman, Russell Vang, Jette Junge, et al.
International Journal of Cancer|September 25, 2018
Risk of CIN3 or worse with persistence of 13 individual oncogenic HPV typesFreja Laerke Sand, Christian Munk, Kirsten Frederiksen, et al.
International Journal of Cancer|August 5, 2015
Factors associated with type-specific persistence of high-risk human papillomavirus infection: A population-based studySigne Stensen, Susanne K Kjaer, Signe M Jensen, et al.
Gynecologic Oncology|February 29, 2012
A binary histologic grading system for ovarian serous carcinoma is an independent prognostic factor: a population-based study of 4317 women diagnosed in Denmark 1978-2006Charlotte Gerd Hannibal, Russell Vang, Jette Junge, et al.
Obstetrics and Gynecology|January 28, 2014
High-risk and low-risk human papillomavirus and the absolute risk of cervical intraepithelial neoplasia or cancerLouise T Thomsen, Kirsten Frederiksen, Christian Munk, et al.
Papillomavirus Research (Amsterdam, Netherlands)|October 28, 2017
Clinical and analytical performance of the BD Onclarity™ HPV assay for detection of CIN2+ lesions on SurePath samplesDitte Møller Ejegod, Jette Junge, Maria Franzmann, et al.
Pageof 4

Showing results (11-20 of 32) with videos related to

Sort By:
Pageof 4
International Journal of Cancer|December 5, 2014
Long-term risk of cervical intraepithelial neoplasia grade 3 or worse according to high-risk human papillomavirus genotype and semi-quantitative viral load among 33,288 women with normal cervical cytologyLouise T Thomsen, Kirsten Frederiksen, Christian Munk, et al.
Gynecologic Oncology|November 13, 2016
A nationwide study of ovarian serous borderline tumors in Denmark 1978-2002. Risk of recurrence, and development of ovarian serous carcinomaCharlotte Gerd Hannibal, Russell Vang, Jette Junge, et al.
The American Journal of Surgical Pathology|March 2, 2017
Long-term Behavior of Serous Borderline Tumors Subdivided Into Atypical Proliferative Tumors and Noninvasive Low-grade Carcinomas: A Population-based Clinicopathologic Study of 942 CasesRussell Vang, Charlotte G Hannibal, Jette Junge, et al.
International Journal of Cancer|March 24, 2016
Human papillomavirus mRNA and DNA testing in women with atypical squamous cells of undetermined significance: A prospective cohort studyLouise T Thomsen, Christian Dehlendorff, Jette Junge, et al.
The American Journal of Surgical Pathology|October 15, 2011
Papillary tubal hyperplasia: the putative precursor of ovarian atypical proliferative (borderline) serous tumors, noninvasive implants, and endosalpingiosisRobert J Kurman, Russell Vang, Jette Junge, et al.
International Journal of Cancer|September 25, 2018
Risk of CIN3 or worse with persistence of 13 individual oncogenic HPV typesFreja Laerke Sand, Christian Munk, Kirsten Frederiksen, et al.
International Journal of Cancer|August 5, 2015
Factors associated with type-specific persistence of high-risk human papillomavirus infection: A population-based studySigne Stensen, Susanne K Kjaer, Signe M Jensen, et al.
Gynecologic Oncology|February 29, 2012
A binary histologic grading system for ovarian serous carcinoma is an independent prognostic factor: a population-based study of 4317 women diagnosed in Denmark 1978-2006Charlotte Gerd Hannibal, Russell Vang, Jette Junge, et al.
Obstetrics and Gynecology|January 28, 2014
High-risk and low-risk human papillomavirus and the absolute risk of cervical intraepithelial neoplasia or cancerLouise T Thomsen, Kirsten Frederiksen, Christian Munk, et al.
Papillomavirus Research (Amsterdam, Netherlands)|October 28, 2017
Clinical and analytical performance of the BD Onclarity™ HPV assay for detection of CIN2+ lesions on SurePath samplesDitte Møller Ejegod, Jette Junge, Maria Franzmann, et al.
Pageof 4